warm, thanks for the heads up about the breast cancer drugs in the news. it would be nice if ENZN's drugs were the topic of the news. They're not, but the delivery system is very similar to ENZN's.
They're are bunch of different things about ENZN that peak the curiosity; the ownership, pipeline, a new CEO and the hiring of the new CFO. I keep asking myself, why does a bean counter leave a sub of Lilly and to go to a small pharmaceutical company that does not have enough cash to support its pipeline through the phase 3 trials?
The only answer I can come up with is- there must be interest from some large companies willing to put up the cash for the trials to continue. Hopefully I'm not being too optimistic!!!